Bleomycin is a medication used to treat cancer. This includes Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, ovarian cancer, and cervical cancer among others. Typically used with other cancer medications, it can be given intravenously, by injection into a muscle or under the skin. It may also be administered inside the chest to help prevent the recurrence of a fluid around the lung due to cancer; however talc is better for this.
|intravenous, intramuscular, subcutaneous, intrapleural, intratumoral|
|Elimination half-life||2 hours|
|Chemical and physical data|
|Molar mass||1415.551 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Common side effects include fever, weight loss, vomiting, and rash. A severe type of anaphylaxis may occur. It may also cause inflammation of the lungs that can result in lung scarring. Chest X-rays every couple of weeks are recommended to check for this. Bleomycin may cause harm to the baby if used during pregnancy. It is believed to primarily work by preventing the making of DNA.
Bleomycin was discovered in 1962. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication. The wholesale cost in the developing world is between US$14 and US$78 a dose. It is made by the bacterium Streptomyces verticillus.
Bleomycin is mostly used to treat cancer. This includes testicular cancer, ovarian cancer, and Hodgkin's disease, and less commonly non-Hodgkin's disease. It can be given intravenously, by intramuscular injection, or under the skin.
The most common side effects are flu-like symptoms and include fever, rash, dermatographism, hyperpigmentation, alopecia (hair loss), chills, and Raynaud's phenomenon (discoloration of fingers and toes). The most serious complication of bleomycin, occurring upon increaing dosage, is pulmonary fibrosis and impaired lung function. It has been suggested that bleomycin induces sensitivity to oxygen toxicity and recent studies support the role of the proinflammatory cytokines IL-18 and IL-1beta in the mechanism of bleomycin-induced lung injury. Any previous treatment with bleomycin should therefore always be disclosed to the anaesthetist prior to undergoing a procedure requiring general anaesthesia. Due to the oxygen sensitive nature of bleomycin, and the theorised increased likelihood of developing pulmonary fibrosis following supplemental oxygen therapy, it has been questioned whether patients should take part in scuba diving following treatment with the drug.
Mechanism of actionEdit
Bleomycin acts by induction of DNA strand breaks. Some studies suggest bleomycin also inhibits incorporation of thymidine into DNA strands. DNA cleavage by bleomycin depends on oxygen and metal ions, at least in vitro. The exact mechanism of DNA strand scission is unresolved, but it has been suggested that bleomycin chelates metal ions (primarily iron), producing a pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals that cleave DNA. An alternative hypothesis states that bleomycin may bind at specific sites in the DNA strand and induce scission by abstracting the hydrogen atom from the base, resulting in strand cleavage as the base undergoes a Criegee-type rearrangement, or forms an alkali-labile lesion. In addition, these complexes also mediate lipid peroxidation and oxidation of other cellular molecules. Therefore, bleomycin is used in combination with doxorubicin in Hodgkins lymphoma, as they have additive and complementary effects on the DNA, since doxorubicin acts by intercalating between DNA strands, and also acts on topoisomerase II enzyme thus relaxing the topoisomerase complexes.
Bleomycin is a nonribosomal peptide that is a hybrid peptide-polyketide natural product. The peptide/polyketide/peptide backbone of the bleomycin aglycon is assembled by the bleomycin megasynthetase, which is made of both nonribosomal peptide synthetase (NRPS) and polyketide synthase (PKS) modules. Nonribosomal peptides and polyketides are synthesized from amino acids and short carboxylic acids by NRPSs and PKSs, respectively. These NRPSs and PKSs use similar strategies for the assembly of these two distinct classes of natural products. Both NRPs and type I PKSs are organized into modules. The structural variations of the resulting peptide and polyketide products are determined by the number and order of modules on each NRPS and PKS protein.
The biosynthesis of the bleomycin aglycon can be visualized in three stages:
- NRPS-mediated formation of P-3A from Ser, Asn, His, and Ala
- PKS-mediated elongation of P-3A by malonyl CoA and AdoMet to yield P-4
- NRPS-mediated elongation of P-4 by Thr to P-5 that is further elongated by β-Ala, Cys, and Cys to get P-6m.
On the basis of the bleomycin structure and the deduced functions of individual NRPS and PKS domains and modules, a linear model for the bleomycin megasynthetase-templated assembly of the bleomycin peptide/polyketide/peptide aglycon was proposed from nine amino acids and one acetate.
Biosynthesis of bleomycin is completed by glycosylation of the aglycones. Bleomycin naturally occurring-analogues have two to three sugar molecules, and DNA cleavage activities of these analogues have been assessed, primarily by the plasmid relaxation and break light assays.
Bleomycin was first discovered in 1966 when the Japanese scientist Hamao Umezawa found anticancer activity while screening culture filtrates of Streptomyces verticillus. Umezawa published his discovery in 1966. The drug was launched in Japan by Nippon Kayaku in 1969. In the US, bleomycin gained FDA approval in July 1973. It was initially marketed in the US by the Bristol-Myers Squibb precursor, Bristol Laboratories, under the brand name Blenoxane.
- "Bleomycin Sulfate". The American Society of Health-System Pharmacists. Archived from the original on 2015-09-08. Retrieved Aug 1, 2015.
- Shaw, P; Agarwal, R (2004). "Pleurodesis for malignant pleural effusions". The Cochrane Database of Systematic Reviews (1): CD002916. doi:10.1002/14651858.CD002916.pub2. PMID 14973997. (Retracted, see doi:10.1002/14651858.cd002916.pub3. If this is an intentional citation to a retracted paper, please replace
- Sneader, Walter (2005). Drug discovery : a history (Rev. and updated ed.). Chichester: Wiley. p. 312. ISBN 9780471899792. Archived from the original on 2016-03-05.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "Bleomycin". International Drug Price Indicator Guide. Retrieved 26 August 2015.
- Kwok, CS; Gibbs, S; Bennett, C; Holland, R; Abbott, R (12 September 2012). "Topical treatments for cutaneous warts". The Cochrane Database of Systematic Reviews. 9 (9): CD001781. doi:10.1002/14651858.CD001781.pub3. PMID 22972052.
- Thompson, Malcolm. "Bleomycin and Anaesthesia" (PDF). Anaesthesia Western Australia. Retrieved 8 September 2017.
- Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H (March 2009). "Role of Proinflammatory Cytokine IL-18 and IL-1β in Bleomycin-induced Lung Injury in Humans and Mice". Am. J. Respir. Cell Mol. Biol. 41 (6): 661–70. doi:10.1165/rcmb.2008-0182OC. PMID 19265174.
- Huls, G.; Ten Bokkel Huinink, D. (2012-05-24). "Bleomycin and scuba diving: to dive or not to dive?". The Netherlands Journal of Medicine. 61 (2): 50–53.
- Takimoto CH, Calvo E. "Principles of Oncologic Pharmacotherapy" Archived 2009-05-15 at the Wayback Machine in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach Archived 2013-10-04 at the Wayback Machine. 11 ed. 2008.
- Hecht, SM (2000). "Bleomycin: new perspectives on the mechanism of action". J. Nat. Prod. 63 (1): 158–168. doi:10.1021/np990549f. PMID 10650103.
- Hindra, H; Yang, D; Teng, Q; Dong, LB; Crnovčić, I; Huang, T; Ge, H; Shen, B (17 March 2017). "Genome Mining of Streptomyces mobaraensis DSM40847 as a Bleomycin Producer Providing a Biotechnology Platform To Engineer Designer Bleomycin Analogues". Organic Letters. 19 (6): 1386–1389. doi:10.1021/acs.orglett.7b00283. PMID 28256838.
- Yang, D; Hindra, H; Dong, LB; Crnovcic, I; Shen, B (23 August 2017). "Engineered production and evaluation of 6'-deoxy-tallysomycin H-1 revealing new insights into the structure-activity relationship of the anticancer drug bleomycin". The Journal of Antibiotics. 71: 97–103. doi:10.1038/ja.2017.93. PMID 28831149.
- Umenzawa, H. et al. J. Antibiot. (Tokyo) Ser. A 1966, 19, 200.
- Song, Nana; Liu, Jun; Shaheen, Saad; Du, Lei; Proctor, Mary; Roman, Jesse; Yu, Jerry (2015). "Vagotomy attenuates bleomycin-induced pulmonary fibrosis in mice". Scientific Reports. 5: 13419. doi:10.1038/srep13419. PMC 4542162. PMID 26289670. Archived from the original on 2016-05-03.
In our studies, mice developed classic PF with structural alteration of the lung following intravenous bleomycin treatment
- Claussen, C.A.; Long, E.C. (1999). "Nucleic Acid Recognition by Metal Complexes of Bleomycin". Chem. Rev. 99 (9): 2797–2816. doi:10.1021/cr980449z. PMID 11749501.
- Shen, B.; Du, L.C.; Sanchez, C.; Edwards, D.J.; Chen, M.; Murrell, J.M. (2001). "The biosynthetic gene cluster for the anticancer drug bleomycin from Streptomyces verticillus ATCC15003 as a model for hybrid peptide-polyketide natural product biosynthesis". Journal of Industrial Microbiology & Biotechnology. 27 (6): 378–385. doi:10.1038/sj.jim.7000194. PMID 11774003.